ShanghaiMay 13, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a global leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced that, due to its relentless efforts and outstanding achievements in advancing sustainable development, the company has been included in the 2026 Dow Jones Best-in-Class World Index (DJ BIC World) and the Dow Jones Best-in-Class Emerging Markets Index (DJ BIC Emerging Markets).
Both indices are based on the S&P Global Corporate Sustainability Assessment (CSA), selecting the top 10% of global sustainability leaders with long-term excellent performance in economic, environmental, and social dimensions. Among them, the DJ BIC World covers the 2,500 largest companies globally in the S&P Global Broad Market Index (S&P Global BMI); the DJ BIC Emerging Markets covers the 800 largest companies across 20 emerging markets.
Based on the 2025 CSA results, WuXi Biologics ranked among the top of its industry, entering the global top 1%, and was included in the S&P Global Sustainability Yearbook for the fourth consecutive year.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of the ESG Committee, stated: “We are deeply honored to be included in the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class Emerging Markets Index. This recognition fully reflects the company’s long-term commitment to sustainable development and its continuously improving comprehensive performance. As a global leader in green biopharmaceutical solutions, WuXi Biologics consistently integrates ESG concepts into its business strategy and operational practices, continuously providing innovative end-to-end solutions to global partners. Looking ahead, we will continue to collaborate with all parties to jointly drive the entire value chain towards a more responsible and sustainable direction.”
In recent years, WuXi Biologics’ sustained investment in sustainable development has been recognized by multiple internationally authoritative ESG rating agencies, including MSCI’s highest ESG AAA rating; EcoVadis Platinum Medal; CDP’s “A List” for climate change, water security, and supplier engagement; Morningstar Sustainalytics’ highest “Negligible Risk” rating and “Industry ESG Leader” and “Regional ESG Leader” designations; inclusion in the FTSE4Good Index Series; ISS ESG’s “Prime” rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index, fully demonstrating the company’s outstanding performance in the field of sustainable development.
About WuXi Biologics
WuXi Biologics (Stock Code: 2269.HK) is a global leading Contract Research, Development, and Manufacturing Organization (CRDMO). Through an open, integrated biopharmaceutical capability and technology platform, the company provides comprehensive end-to-end services to help partners discover, develop, and manufacture biologics, realizing the entire process from concept to commercial production, accelerating global biopharmaceutical R&D processes, reducing R&D costs, and benefiting patients worldwide.
Leveraging a global network connecting China, the United States, Ireland, Germany, and Singapore, WuXi Biologics brings together over 13,000 employees, including industry experts and scientists in biologics R&D and manufacturing, technological innovation, and operational excellence. With its leading technology platforms and deep expertise, the company provides efficient, cost-effective, and scalable biopharmaceutical solutions to precisely meet customer needs at different stages. Additionally, the company systematically integrates digital capabilities and infrastructure into the entire value chain of biologics R&D, laboratory operations, and manufacturing, transforming data, computing, and predictive capabilities into a more transparent customer collaboration experience, faster R&D processes, smarter operational management, and more efficient production delivery. As of the end of December 2025, WuXi Biologics had helped customers research and develop a total of 945 comprehensive projects, including 74 Phase III clinical projects and 25 commercial manufacturing projects, with complex molecule projects accounting for over 50% of the company’s total project count.
WuXi Biologics regards sustainable development as the cornerstone of long-term business growth. The company continuously promotes green innovative technologies, providing global partners with advanced end-to-end green CRDMO solutions, while achieving outstanding ESG performance. Upholding the concept of creating shared value, the company collaborates with stakeholders to build a sustainable ecosystem, driving both social value and ecological benefits through responsible operational models, achieving synergistic empowerment across the entire value chain.
For more information, please visit: www.wuxibiologics.com